Chuan-Shu Chen

Taichung Veterans General Hospital

Papers

7

Total Citations

100

H-Index

6

About

Dr. Chuan-Shu Chen is a leading urologic oncologist and researcher whose work bridges molecular genetics and robotic surgery to improve prostate cancer management. His research focuses on the role of long noncoding RNAs (lncRNAs) in prostate cancer susceptibility and progression, particularly through genetic polymorphisms. He has demonstrated that variants in GAS5 (rs145204276) significantly influence prostate cancer risk and clinicopathologic features (27 citations), while polymorphisms in MALAT1 are associated with lymph node metastasis (15 citations). Dr. Chen has also investigated how H19 polymorphisms and carbonic anhydrase 9 expression can refine risk stratification, especially for patients with low PSA levels. Beyond genetics, he is a pioneer in robotic urologic surgery, having standardized robotic-assisted laparoscopic radical prostatectomy through a landmark series of 1,200 cases performed by a single surgeon. His long-term outcomes study on robotic partial nephrectomy for renal angiomyolipoma (17 citations) further showcases his surgical expertise. With over 100 cumulative citations across his most influential works, Dr. Chen’s integrated approach—from molecular biomarkers to advanced surgical technique—is shaping personalized treatment strategies for urologic cancers.

Research Focus

Key Achievements

6
H-Index
7
Papers
100
Total Citations
14
Avg Citations/Paper
🏆 Most Cited Paper
Impact of GAS5 genetic polymorphism on prostate cancer susceptibility and clinicopathologic characteristics
27 citations · 2019
📈 Most Prolific Year: 2019 (2 Papers)
🤝 Key Collaborators: 19
🏛 Institutions: Taichung Veterans General Hospital

Top Papers

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago